While HMOX1 protein levels were significantly higher in the simvastatin-treated group (p < 0.05), the expression of the NRF2 target genes HMOX1, NQO1, and GCLM in AAA tissue did not show significant differences between the treated and untreated groups [52]. The gene discussed is HMOX1; the disease is triple-A syndrome.